Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center prospective, single-arm, non-randomized, pivotal study that will continue to access the feasibility of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring right ventricular outflow tract correction or reconstruction due to congenital heart malformations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xeltis Pulmonary Valved Conduit Safety and Performance Study

NCT03405636

Heart Defects, Congenital

WITHDRAWN NA

Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction

NCT02700100

Congenital Heart Disease

UNKNOWN NA

Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis

NCT02377700

Heart Defects, Congenital

COMPLETED NA

PV Loop & Coarctation Study

NCT05362721

Coarctation of Aorta

RECRUITING

Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort

NCT00740870

Congenital Heart Defects Dysfunctional Right Ventricular Outflow Tract Conduits

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Defect, Congenital

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xeltis Bioabsorbable Pulmonary Valved Conduit

The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.

The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:

* Tetralogy of Fallot
* Truncus Arteriosus
* Pulmonary Atresia
* Transposition of Great Arteries with Ventricular Septal Defect
* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes

In addition, the PV conduit can be used for the following indications:

* replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).
* Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve.

Group Type EXPERIMENTAL

Xeltis Bioabsorbable Pulmonary Valved Conduit

Intervention Type DEVICE

Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xeltis Bioabsorbable Pulmonary Valved Conduit

Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient requiring RVOT reconstruction, suitable for 16 mm,18 mm, 20 mm and 22 mm valved conduit.
2. Male or Female.
3. Age \> 2 years and \< 22 years.
4. Right Ventricular to Pulmonary Artery peak gradient \> 35mm Hg or moderate or severe Pulmonary regurgitation (≥3+), or have both (except for the patients undergoing a Ross procedure)
5. The patient, and the patient's parent / legal representative where appropriate, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent by signing the approved informed consent form.
6. The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.

Exclusion Criteria

1. Need for or presence of prosthetic heart valve at other position.
2. Need for concomitant surgical procedures (non-cardiac).
3. Patients with previously implanted pacemaker (including defibrillators), or mechanical valves.
4. Active infection or requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics) or viral infection.
5. Active endocarditis.
6. Leukopenia, defined as White Blood cell Count \< than:

* 2-12 years: 5.0 ×103 /μL
* 12 years - Adult:
* Male: 4.5×103 /μL
* Female: 4.5 ×103 /μL
7. Acute or chronic anemia, defined as Hemoglobin \< than:

* 2-12 years 11.5 g /dl
* 12-18:
* Male: 13 g /dl
* Female 12 g /dl
* Adult:
* Male: 13.5 g /dl
* Female: 12 g /dl Patients can be transfused to meet eligibility criteria
8. Thrombocytopenia, defined as Platelet count \< than:

* 150,000/mm3 Patients can be transfused to meet eligibility criteria
9. Severe chest wall deformity, which would preclude placement of the PV conduit.
10. Pulmonary hypertension (≥ half of systemic systolic pressure)
11. Right ventricular outflow tract aneurysm.
12. Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials. .
13. Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs.
14. Subject has chronic inflammatory / autoimmune disease.
15. Need for emergency cardiac or vascular surgery or intervention.
16. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year.
17. Currently participating, or participated within the last 30 days, in an investigational drug or device study.
18. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
19. Pregnancy.
20. Females who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
21. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance.

Minimum Eligible Age

2 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No